Find investors
← Back to all investors
TS
ResearchedAngel Investors

Torsten Schneider

Investment Director

Angel InvestorsSeed Round
Pitch Torsten

Get their honest, personalized take on your startup.

Sign in to pitch Torsten

At a glance

Full Name
Torsten Schneider
Title
Partner
Firm
Afinum Management GmbH
Firm Type
Private equity firm
Investment Stage
Buyout / growth equity for established SMEs
Check Size
EUR 30-150 million purchase prices; selectively smaller add-on acquisitions
Target Company Profile
Founder- or family-owned, profitable medium-sized companies; typically EUR 20-200 million revenue and approximately EUR 5-20 million EBITDA; majority stakes up to 100%
Sector Focus
Software & TMT / Tech Services, Healthcare, Industrial Technology, Consumer & Internet
Geographic Focus
Germany, Switzerland, Austria
Location
Munich, Bavaria, Germany

Background

Torsten Schneider is a Partner at Afinum Management GmbH, a Munich-headquartered private equity firm focused on majority investments in medium-sized DACH companies. Afinum’s current public materials describe the firm as an investor in founder- and family-owned, profitable companies, with an emphasis on succession situations, management buyouts / buy-ins, group-building strategies, and shareholder-structure optimization.

Afinum announced in early 2023 that Schneider had been promoted to Partner, alongside Elias Bitzer. The firm stated that Schneider joined Afinum in September 2015 and, before that, worked as a strategy consultant with The Boston Consulting Group in Frankfurt and Munich. Afinum’s career page also cites Burkhard von Wangenheim, Kai Roolf, and Torsten Schneider as examples of internal development into Partner roles.

A ContactOut profile adds that Schneider worked at BCG from August 2011 to July 2015 in the Corporate Finance Task Force and had earlier M&A / corporate finance experience at J.P. Morgan, Rothschild, and KPMG. The same profile lists his education as an MSc in International Business / Finance from HEC Paris, a BBA from ESB Business School at Reutlingen University, and a business finance degree from Edinburgh Napier University.

Investment Thesis & Focus

  • Afinum focuses on “medium-sized companies in the DACH region” that are founder- or family-owned, profitable, and active in one of its target sectors.
  • The firm’s current buyout strategy targets succession situations, management buyouts / buy-ins, development of grouped business concepts, and shareholder-structure optimization.
  • Afinum typically seeks clear majority stakes up to 100%, with revenue of EUR 20-200 million, EBITDA of about EUR 5-20 million, and purchase prices of EUR 30-150 million.
  • Sector focus is concentrated in Software & TMT / Tech Services, Healthcare, Industrial Technology, and Consumer & Internet.
  • Afinum’s stated operating approach is partnership-oriented: the firm says it works with founders and management teams to define growth roadmaps and create “category champions of tomorrow.”
  • Afinum states that it is willing to support companies through strategic levers such as value-creation platforms, add-on acquisitions, operational improvements, and expansion into new market areas.

Notable Investments

  • mymediset + p36: Current Afinum 9 investment in software for Life Sciences and MedTech supply-chain and regulatory-compliance management; Afinum entered mymediset in 2023 and p36 in 2026.
  • Tisso Natural Products: Current healthcare investment entered in 2021; Tisso is a Wenden-based manufacturer and premium brand for therapeutic food supplements.
  • Kappa optronics: Realised industrial-technology investment entered in 2017; Afinum announced in January 2026 that it had agreed to sell Kappa to Theon International after the company more than doubled EBITDA under Afinum ownership.
  • Threema: Realised software investment entered in 2020; Afinum announced in January 2026 that it had agreed to sell Threema to Comitis Capital after tripling annual recurring revenue under Afinum ownership.
  • CloudFit: Objektkultur + Inway Systems: Current Software & TMT investment; Afinum entered Objektkultur in 2024 and added Inway Systems in 2025 to build a Microsoft Dynamics / BizApps platform.
  • ProJect Pharmaceutics: Afinum announced in September 2025 an investment in the Munich-area biologics and complex small-molecule formulation-development specialist, the eleventh and final platform investment for Afinum 9.
  • DPS Engineering: Afinum announced in December 2025 an investment in the financial-services software and application specialist as the first platform investment of the newly launched Afinum X fund.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.